Fate Therapeutics (FATE)
(Delayed Data from NSDQ)
$3.80 USD
-0.07 (-1.81%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $3.80 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth A Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.80 USD
-0.07 (-1.81%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $3.80 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth A Momentum F VGM
Zacks News
Fate Therapeutics (FATE) Jumps: Stock Rises 8.9%
by Zacks Equity Research
Fate Therapeutics (FATE) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Fate Therapeutics (FATE) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Fate Therapeutics (FATE) delivered earnings and revenue surprises of -29.17% and -72.98%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Nobel Prize for Cancer Immunotherapy & Biotech ETFs to Buy
by Neena Mishra
2018 Nobel Prize for medicine was awarded for immunotherapy research. Here is what investors need to know about stocks and ETF focused on this innovative area.
Fate Therapeutics (FATE) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Fate Therapeutics (FATE) delivered earnings and revenue surprises of -32.14% and -19.26%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
3 Stocks Under $10 That Surged Today
by Benjamin Rains
Here at Zacks, we encourage investors to follow our proven stock-picking system, which places a great deal of emphasis on earnings estimate revisions in order to find winning stocks. However, we also always seek to cover stocks, big and small, that are making noteworthy moves.
Fate Therapeutics (FATE) Jumps: Stock Rises 5.7%
by Zacks Equity Research
The shares of Fate Therapeutics (FATE) rose nearly 6% yesterday.
Are Options Traders Betting on a Big Move in Fate Therapeutics (FATE) Stock?
by Zacks Equity Research
Investors in Fate Therapeutics (FATE) need to pay close attention to the stock based on moves in the options market lately.
Surging Earnings Estimates Signal Good News for Fate Therapeutics (FATE)
by Zacks Equity Research
Fate Therapeutics (FATE) could be an interesting play for investors as it sees solid activity on the earnings estimate revision.
Zacks.com featured highlights: Apollo Investment, Ballard Power Systems, Cymabay Therapeutics, Fate Therpautics and Oclaro
by Zacks Equity Research
Zacks.com featured highlights: Apollo Investment, Ballard Power Systems, Cymabay Therapeutics, Fate Therpautics and Oclaro
Explosive Stocks Under $10
by Kevin Matras
Kevin Matras looks for stocks under $10 with explosive potential. Highlighted stocks include AINV, BLDP, CBAY, FATE and OCLR.
Fate Therapeutics (FATE) Shares March Higher, Can It Continue?
by Zacks Equity Research
Fate Therapeutics, Inc. (FATE) has been on the move lately as the stock has risen by 43.4% in the past four weeks, and it is currently trading well above its 20-Day SMA
The Zacks Analyst Blog Highlights: Gilead Sciences, Celgene, Fate Therapeutics, Exelixis and Akebia Therapeutics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Gilead Sciences, Celgene, Fate Therapeutics, Exelixis and Akebia Therapeutics
Fate Therapeutics (FATE) Shares March Higher, Can It Continue?
by Zacks Equity Research
Fate Therapeutics, Inc. (FATE) has been on the move lately as the stock has risen by 14.8% in the past four weeks, and it is currently trading well above its 20-Day SMA